In silico model of mechano-biochemical bone remodeling characterizes the therapeutic effects of osteoporosis drugs depending on the action mechanism

• An in silico model of bone remodeling incorporating pharmacodynamics was developed. • Computer simulation of drug treatment for osteoporosis was performed. • Changes in bone morphology and bone cell dynamics were investigated simultaneously. • Medication simulation enabled characterization of the drugs’ therapeutic effects. • Dependence of osteoporosis drug efficacy on the action mechanism was demonstrated. Osteoporosis stems from an imbalance between bone resorption and formation during bone remodeling, a mechano-biochemical coupling event that intercellular signaling regulates among the bone cells in response to the mechanical environment. Osteoporosis treatment necessitates the modulation of impaired bone remodeling by drug administration to restore an appropriate balance in bone resorption–formation. Characterizing the therapeutic effects of osteoporosis drugs based on their molecular mechanisms of action is crucial to prevent adverse effects and improve the therapeutic efficacy. Herein, we characterized the therapeutic effects of osteoporosis drugs using an in silico model of mechano-biochemical bone remodeling, enabling examination of its spatial and temporal behaviors. We conducted computer simulations to assess osteoporosis drug treatments using two drugs with different mechanisms of action: an anti-receptor activator of nuclear factor-κB ligand (RANKL) antibody (denosumab) and a RANKL production inhibitor. Both drugs restored functionally-adapted trabecular bone morphology when dosages were appropriately adjusted. However, denosumab exhibited more stable therapeutic effects despite dosage changes in osteoporosis treatment. Thus, our medication simulation effectively depicted the therapeutic effects of osteoporosis drugs, illustrating their efficacy based on their mechanisms of action. We expect that medication simulations utilizing an in silico model of mechano-biochemical bone remodeling will expedite the drug discovery process by thoroughly analyzing molecular, cellular, tissue, and organ dynamics during drug treatment.

Authors

Institutions

Publication Details

Journal
Biomedical Engineering Advances
Published
2025-05-02
DOI
https://doi.org/10.1016/j.bea.2025.100176
Citations
1
Primary Topic
Bone Metabolism and Diseases
Type
article
Field-Weighted Citation Impact
0.81

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

In silico model of mechano-biochemical bone remodeling characterizes the therapeutic effects of osteoporosis drugs depending on the action mechanism

Yoshitaka KAMEO, Young Kwan Kim, Taiji ADACHI, Yuki MIYA et al.
1 citations
Biomedical Engineering Advances
Bone Metabolism and Diseases
0.81
article

In silico model of mechano-biochemical bone remodeling characterizes the therapeutic effects of osteoporosis drugs depending on the action mechanism

Yoshitaka KAMEO, Young Kwan Kim, Taiji ADACHI, Yuki MIYA, Kei Imai
article en
1 citations

Abstract

• An in silico model of bone remodeling incorporating pharmacodynamics was developed. • Computer simulation of drug treatment for osteoporosis was performed. • Changes in bone morphology and bone cell dynamics were investigated simultaneously. • Medication simulation enabled characterization of the drugs’ therapeutic effects. • Dependence of osteoporosis drug efficacy on the action mechanism was demonstrated. Osteoporosis stems from an imbalance between bone resorption and formation during bone remodeling, a mechano-biochemical coupling event that intercellular signaling regulates among the bone cells in response to the mechanical environment. Osteoporosis treatment necessitates the modulation of impaired bone remodeling by drug administration to restore an appropriate balance in bone resorption–formation. Characterizing the therapeutic effects of osteoporosis drugs based on their molecular mechanisms of action is crucial to prevent adverse effects and improve the therapeutic efficacy. Herein, we characterized the therapeutic effects of osteoporosis drugs using an in silico model of mechano-biochemical bone remodeling, enabling examination of its spatial and temporal behaviors. We conducted computer simulations to assess osteoporosis drug treatments using two drugs with different mechanisms of action: an anti-receptor activator of nuclear factor-κB ligand (RANKL) antibody (denosumab) and a RANKL production inhibitor. Both drugs restored functionally-adapted trabecular bone morphology when dosages were appropriately adjusted. However, denosumab exhibited more stable therapeutic effects despite dosage changes in osteoporosis treatment. Thus, our medication simulation effectively depicted the therapeutic effects of osteoporosis drugs, illustrating their efficacy based on their mechanisms of action. We expect that medication simulations utilizing an in silico model of mechano-biochemical bone remodeling will expedite the drug discovery process by thoroughly analyzing molecular, cellular, tissue, and organ dynamics during drug treatment.

Biomedical Engineering AdvancesVol. 9
Shibaura Institute of Technology (JP), Kyoto University (JP), The University of Tokyo (JP)
Japan Society for the Promotion of Science, Japan Science and Technology Agency, Core Research for Evolutional Science and Technology
Good health and well-being
Openalex Percentile: Top 28%
Bone Metabolism and Diseases
0.81
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.